Drugs / Biological Ventricular Assist Tissue
Biological Ventricular Assist Tissue
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04396899 | Feb 2020 → Dec 2027 expected | heart failure | University Medical Center Goettingen | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 4
| Date | Issuer | Release |
|---|---|---|
| 2026-05-28 | Repairon GmbH | Results Repairon Announces Publication of Clinical Trial Results for Engineered Human Heart Muscle Tissue in the New England Journal of Medicine repairon.de ↗ |
| 2025-01-01 | Repairon GmbH | Results Repairon announces positive clinical outcomes of engineered heart muscle as reparative therapy for advanced heart failure reported at the Scientific Sessions of the American Heart Association repairon.de ↗
Yesterday at the Ernest N Morial Convention Center, latest clinical trial findings were disclosed on the use of human engineered heart muscle as biological ventricular assist tissue (BioVAT) transplants in patients with advanced heart failure. |
| 2023-11-12 | Repairon GmbH | Results BioVAT-HF Phase 1/2 reveals first evidence for effective heart repair in Advanced Heart Failure repairon.de ↗
The first-in-human dose-finding part of BioVAT-HF demonstrated that EHM were safe and well tolerated at all tested doses. |
| 2023-04-04 | Repairon GmbH | Results Repairon announces completion of dose-finding part of BioVA T-HF Phase 1/2 trial in Advanced Heart Failure repairon.de ↗
Feasibility and safety demonstrated in patients with advanced heart failure |
All press releases naming this drug 4 releases
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Biological Ventricular Assist Tissue | “designated "Biological Ventricular Assist Tissue" or BioVAT” NCT04396899 ↗ |
| Known as | BioVAT | “designated "Biological Ventricular Assist Tissue" or BioVAT” NCT04396899 ↗ |
| Known as | EHM | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04396899 ↗ |
| Action | Restore | “for cardiac remuscularization” PMID 42202318 ↗ May 2026 |
| Modality | Cell therapy | “composed of cardiomyocytes and stromal cells derived from allogeneic induced pluripotent stem cells” PMID 42202318 ↗ May 2026 |
| Route | Other | “Implantation of EHM on dysfunctional left or right ventricular myocardium” NCT04396899 ↗ |